Story
Novo Nordisk Enters $1.4 Billion Deal with Orbis Medicines for Oral Cardiometabolic Drugs
Novo Nordisk has entered into a strategic drug discovery and licensing agreement with privately held Orbis Medicines to develop oral treatments for cardiometabolic diseases. The deal, announced Thursday, could be worth up to $1.4 billion for Orbis Medicines.
Details of the Agreement
The collaboration is structured to include a series of payments to Orbis. According to the announcement, the total potential value of $1.4 billion comprises upfront and milestone payments, supplemented by tiered royalties on any future product sales.
As part of the deal, Novo Nordisk will also make a strategic investment in Orbis. However, the companies did not disclose the specific financial terms, including the size of the initial payment, the breakdown of milestone targets, or the amount of the investment.
Strategic Rationale and Technology
The partnership aims to convert existing injectable therapies for cardiometabolic conditions into more convenient oral medications. This is a significant objective in the pharmaceutical industry, as oral drugs can improve patient adherence and expand market access.
AdTo achieve this, the collaboration will leverage Orbis's proprietary, AI-enabled nGen platform. The platform is designed to discover and develop macrocycles, a class of molecules well-suited for creating oral drugs that can target complex diseases typically treated with injections. The agreement will focus on multiple therapeutic targets within the cardiometabolic space.
Market Context
This deal underscores Novo Nordisk's strategy to maintain its leadership position in the highly competitive cardiometabolic market. By investing in novel technologies that promise oral alternatives to blockbuster injectable drugs, the company is seeking to secure its next generation of treatments.
For Orbis Medicines, the partnership provides a major validation of its technology platform from a leading global pharmaceutical company. The agreement also supplies significant funding and resources to advance its research and development programs.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.
Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.
Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.
DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.